Abstract Number: 1306 • ACR Convergence 2020
High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred with Anterior Uveitis and Chronic Back Pain
Background/Purpose: To reduce the diagnostic delay in axial spondyloarthritis (axSpA), Rheumatology and Ophthalmology guidelines recommend to refer patients with acute anterior uveitis (AAU) and chronic…Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…Abstract Number: 1863 • ACR Convergence 2020
Clinical History as Tool for Diagnosis and Classification of Patients with Ankylosing Spondylitis (Axial Spondyloarthritis): Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Background/Purpose: Lack of sensitivity or specificity of symptoms may induce uncertainty in diagnosis and classification of AS/axSpA. We investigated if balanced sensitivity and specificity of…Abstract Number: 1891 • ACR Convergence 2020
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…Abstract Number: 0038 • ACR Convergence 2020
Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study
Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…Abstract Number: 0448 • ACR Convergence 2020
Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A mutlicenter study with 806 patients.
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) due to a process of accelerated atherosclerosis. The disease-related factors involved in this…Abstract Number: 1309 • ACR Convergence 2020
Prevalence of Undiagnosed Axial Spondyloarthritis Among Patients with Inflammatory Bowel Disease: A Secondary Care Cross-Sectional Study
Background/Purpose: Axial spondyloarthritis (axSpA) is closely related to inflammatory bowel disease (IBD), however contemporary data on the burden of hidden disease in the IBD population…Abstract Number: 1359 • ACR Convergence 2020
Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to…Abstract Number: 1867 • ACR Convergence 2020
Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis in Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Background/Purpose: A diagnosis of (early) axial spondyloarthritis (axSpA) is based on pattern recognition, which can be challenging and may change over time. The aim of…Abstract Number: 1892 • ACR Convergence 2020
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is adopted to evaluate the degree of disease activity and the inflammatory response in AS patients. ASDAS score…Abstract Number: 0080 • ACR Convergence 2020
Understanding Ankylosing Spondylitis –
Background/Purpose: Rheumatology is underrepresented in the medical training of students in Germany. [1] Tools and methods are needed to inspire young students for specialist training…Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…Abstract Number: 1310 • ACR Convergence 2020
Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
Background/Purpose: Multiple studies have confirmed that the gut and stool microbiome in ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are distinct from healthy controls,…Abstract Number: 1362 • ACR Convergence 2020
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of axial spondyloarthritis (axSpA). However, they carry some disadvantages,…Abstract Number: 1868 • ACR Convergence 2020
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Background/Purpose: The aim of this study was to compare quality of life (QoL) between chronic back pain (CBP) patients with and without a diagnosis of…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 67
- Next Page »